Compare Harmony Gold Mining Co. (HMY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Harmony Gold (HMY) trades at $19.89, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported robust 2024 results with $61.38B revenue and $8.59B net income, supported by a strategic pivot toward gold-copper production. Recent earnings have been mixed, with a Q4 2025 miss but prior beats.

The outlook is cautiously optimistic due to diversification benefits and solid cash flow, but risks include Fed rate sensitivity and execution challenges. Analyst sentiment is mixed with a majority Hold rating, reflecting balanced near-term prospects amid macroeconomic uncertainties.

Regeneron Pharmaceuticals (REGN) trades at $794.71, down 1.65% on the day, with strong fundamentals including a P/E of 19.72 and net income margin of 27.86%. The stock is in a bullish technical trend, supported by moving averages, though RSI levels indicate overbought conditions. Recent quarterly EPS results have consistently beaten expectations, and the company maintains robust cash flow from operations of $4.98 billion in 2025. However, multiple class action lawsuits related to clinical trial disclosures present a near-term headwind.

The outlook remains positive due to earnings strength and analyst consensus, but legal risks and high valuation multiples warrant caution. Upside is supported by product growth in Eylea HD and Dupixent, while downside risks include litigation outcomes and potential regulatory scrutiny. The stock trades above the consensus price target of $756.93, suggesting limited near-term upside from current levels.